Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

8.93
+0.01000.11%
Post-market: 8.90-0.0300-0.34%19:30 EDT
Volume:763.53K
Turnover:6.81M
Market Cap:633.21M
PE:-7.15
High:9.05
Open:8.84
Low:8.78
Close:8.92
52wk High:11.45
52wk Low:4.50
Shares:70.91M
Float Shares:67.62M
Volume Ratio:0.64
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.47
PE(LYR):-5.65

Loading ...

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

TIPRANKS
·
May 19

Sagimet Biosciences files Form 3 for Chief Medical Officer Andreas Grauer

Reuters
·
May 15

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 14

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

TIPRANKS
·
May 14

Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 13

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire
·
May 13

Sagimet Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

BRIEF-Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates

Reuters
·
May 12

Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate

Benzinga Earnings
·
May 12

Sagimet Q1 FY26 net loss narrows to $10.7 million; R&D expense drops to $7 million

Reuters
·
May 12

Press Release: Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
May 12

Sagimet plans U.S. Phase 3 denifanstat acne trial start in H2 2026

Reuters
·
May 11

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

GlobeNewswire
·
May 11

Sagimet Biosciences Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 08

Sagimet Biosciences Inc : Canaccord Genuity Raises Target Price to $49 From $28

THOMSON REUTERS
·
May 05

Sagimet Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 04

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTrading

TIPRANKS
·
May 04

Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating

MT Newswires Live
·
May 01

Sagimet Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 30